查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1813403

奈米技术药物植入市场预测（至 2032 年）：按产品类型、材料、治疗领域、植入部位、最终用户和地区进行的全球分析

Nanotech Drug Implants Market Forecasts to 2032 - Global Analysis By Product Type, Material, Therapeutic Area, Implantation Site, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球奈米技术药物植入物市场预计在 2025 年达到 2.566 亿美元，到 2032 年将达到 5.534 亿美元，预测期内的复合年增长率为 11.6%。

奈米技术药物植入是一种先进的医疗设备，利用奈米技术进行可控、局部和持续的药物传输。与传统方法相比，奈米技术药物植入物旨在提高治疗效果、减少副作用并增强患者依从性。其治疗领域包括肿瘤、心血管疾病、糖尿病和神经病变。市场成长的动力来自慢性病发病率的上升、个人化医疗的需求以及奈米技术的持续进步。製药和医疗技术产业之间的合作正在加速技术创新，使奈米技术药物植入成为长期治疗解决方案的变革性方法。

慢性病增多

在全球范围内，心血管疾病、糖尿病和癌症等慢性疾病的发生率不断上升，是奈米技术药物植入物市场的主要驱动力。此类先进的植入能够直接在目标部位控制并持续释放药物，从而提供卓越的治疗效果，提高患者的依从性和治疗效果。这种从传统大剂量投药模式转移，满足了慢性疾病长期管理的需求。此外，不断增长的患者群体需要创新的药物输送解决方案，因此，需要对基于奈米技术的植入式设备进行大量投资和开发，以满足尚未满足的临床需求。

复杂的监管核准途径

美国食品药物管理局 (FDA) 和欧洲药品管理局 (EMA) 等机构严格而复杂的监管核准流程限制市场成长。奈米技术植入被归类为组合产品，需要对药物和器械组件进行严格评估，从而延长了上市时间并增加了研发成本。此外，由于这些技术的新颖性，法律规范通常缺乏，为製造商带来了不确定性。这需要进行大量的临床前和临床试验来证明其安全性和有效性，这为新参与企业设定了巨大的进入壁垒，并可能限製商业产品上市的速度。

开发个人化医疗解决方案

药物基因组学和生物标记识别技术的进步使得我们能够开发出根据个体基因特征和特定疾病病理生理学量身定制的植入植入。这不仅有助于制定精准的给药方案，改善治疗效果，同时最大限度地减少副作用。此外，智慧感测器的整合有助于即时监测和自适应药物释放，从而形成闭合迴路系统。这种客製化趋势正在开闢新的收益来源，并促进製药公司和医疗设备工程师之间的合作。

复杂的监管核准途径

不断演变且不一致的国际法规可能会带来不可预见的合规挑战，并延迟产品在关键市场的上市。上市后监管问题和召回可能会引发更严格的审查，从而增加製造商的营运风险和责任。在这种环境下，持续在监管事务上投入大量资金会分散核心研发活动的资源，并可能阻碍对下一代风险更高的创新产品的投资，从而威胁到长期的市场渗透。

COVID-19的影响：

新冠疫情最初扰乱了奈米技术药物植入市场，导致供应链严重中断，非必要临床试验取消，减缓了产品开发。选择性手术的取消也暂时降低了某些器械的植入率。然而，这场危机随后又起到了催化剂的作用，凸显了对先进、自主给药系统（可最大程度减少就诊次数）的迫切需求。此外，监管部门对疫情相关创新的反应加快，以及对生物医学研究的投入活性化，预计将刺激技术创新，并对市场的长期成长轨迹产生正面影响。

预计聚合物市场在预测期内将占据最大份额

由于PLGA和PLA等可生物降解聚合物的广泛应用，预计聚合物领域将在预测期内占据最大的市场份额。这些材料拥有卓越的生物相容性、可调节的降解动力学以及FDA核准产品中良好的业绩记录。其多功能性使其能够封装从小分子到生技药品的各种治疗剂。此外，其成熟的生产过程和良好的安全性使其成为许多现有和正在研发的奈米技术植入药物的首选材料，巩固了其主导地位。

预计智慧/主动植入领域在预测期内将以最高的复合年增长率成长。

预计在预测期内，智慧/主动植入领域将实现最高成长率，这得益于响应式药物传输系统的技术进步。这些植入配备感测器和致动器，可根据特定的生理触发因素（例如血糖浓度闭合迴路酶活性的变化）释放治疗药物。它们能够实现即时监测和闭环回馈，从而为慢性疾病管理提供无与伦比的治疗控制。此外，与数位健康平台和物联网的整合正在患者资料管理和个人化治疗领域开闢新的领域，吸引大量投资并推动快速成长。

比最大的地区

预计北美地区将在预测期内占据最大的市场份额。这得归功于其完善的医疗基础设施、高昂的医疗成本以及大型製药和医疗设备公司的强大影响力。此外，政府对奈米技术研究的资助、慢性病的高发生率以及相对简化的创新产品法规环境，也促进了这些技术的快速应用。美国主要市场参与者的集中以及先进的临床研究设施巩固了北美作为该市场收益领导者的地位。

复合年增长率最高的地区：

预计亚太地区在预测期内的复合年增长率最高。这项加速成长的驱动力包括：医疗保健可近性的扩大、可支配收入的提高，以及中国和印度等国政府措施。此外，该地区慢性病患者人数呈上升趋势，导致未满足的临床需求增加。医疗旅游业的成长、本地製造能力的提升以及生物医学研发投资的增加，是推动亚太地区成为奈米技术药物植入物快速成长市场的关键因素。

免费客製化服务：

此报告的订阅者可以使用以下免费自订选项之一：

  • 公司简介
    • 对最多三家其他市场公司进行全面分析
    • 主要企业的SWOT分析（最多3家公司）
  • 区域细分
    • 根据客户兴趣对主要国家进行的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 研究途径
  • 研究材料
    • 主要研究资料
    • 次级研究资讯来源
    • 先决条件

第三章市场走势分析

  • 驱动程式
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 最终用户分析
  • 新兴市场
  • COVID-19的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买方的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球奈米技术药物植入物市场（依产品类型）

  • 可生物降解植入
  • 不可生物降解的植入
  • 智慧/主动植入

6. 全球奈米技术药物植入物市场（依材料）

  • 聚合物
  • 脂质基
  • 金属/无机
  • 其他成分

7. 全球奈米技术药物植入物市场（依治疗领域）

  • 肿瘤学
  • 神经病学
  • 心血管系统
  • 内分泌学
  • 眼科
  • 感染疾病
  • 其他治疗领域

8. 全球奈米技术药物植入市场（依植入部位）

  • 皮下
  • 颅内
  • 腹腔内
  • 眼
  • 其他部分

9. 全球奈米技术药物植入物市场（按最终用户）

  • 医院和诊所
  • 专业护理中心
  • 门诊手术中心

第十章全球奈米技术药物植入物市场（按地区）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十一章 重大进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十二章 公司概况

  • Abbott
  • AstraZeneca
  • Bristol-Myers Squibb
  • Celgene Corporation
  • Johnson & Johnson
  • Merck
  • Moderna
  • Nanobiotix
  • Nanoform
  • Novartis
  • Pfizer
  • Roche
  • Sanofi
  • Thermo Fisher Scientific
  • Medtronic
  • Straumann Holding
  • Gilead Sciences
  • Jazz Pharmaceuticals
Product Code: SMRC30852

According to Stratistics MRC, the Global Nanotech Drug Implants Market is accounted for $256.6 million in 2025 and is expected to reach $553.4 million by 2032 growing at a CAGR of 11.6% during the forecast period. Nanotech drug implants are advanced medical devices that use nanotechnology for controlled, localized, and sustained drug delivery. They are designed to improve treatment efficacy, reduce side effects, and enhance patient compliance compared to conventional methods. Therapeutic areas include oncology, cardiovascular diseases, diabetes, and neurological disorders. Market growth is driven by increasing chronic disease prevalence, demand for personalized medicine, and ongoing nanotechnology advancements. Collaborations between the pharma and medtech industries are accelerating innovation, positioning nanotech drug implants as a transformative approach in long-term therapeutic solutions.

Market Dynamics:

Driver:

Rising prevalence of chronic diseases

The escalating global incidence of chronic conditions, such as cardiovascular diseases, diabetes, and cancer, is a primary driver for the nanotech drug implants market. These advanced implants offer superior therapeutic efficacy through controlled, sustained drug release directly at the target site, improving patient compliance and treatment outcomes. This paradigm shift from conventional bolus doses addresses the long-term management needs of chronic illnesses. Additionally, the growing patient population necessitates innovative drug delivery solutions, thereby fueling significant investment and development in nanotechnology-based implantable devices to meet unmet clinical demands.

Restraint:

Complex regulatory approval pathways

The market growth is constrained by stringent and complex regulatory approval processes mandated by agencies like the FDA and EMA. Nanotech implants are classified as combination products, involving rigorous evaluation of both the drug and the device component, which prolongs time-to-market and escalates R&D expenditures. Moreover, the novel nature of these technologies often lacks established regulatory frameworks, creating uncertainty for manufacturers. This necessitates extensive preclinical and clinical trials to demonstrate safety and efficacy, acting as a significant barrier to entry for new players and potentially limiting the pace of commercial product launches.

Opportunity:

Development of personalized medicine solutions

Advances in pharmacogenomics and biomarker identification enable the development of implants tailored to an individual's genetic profile and specific disease pathophysiology. This allows for precise dosing regimens and improved therapeutic outcomes while minimizing adverse effects. Furthermore, the integration of smart sensors can facilitate real-time monitoring and adaptive drug release, creating a closed-loop system. This trend towards customization is opening new revenue streams and fostering collaborations between pharmaceutical companies and medical device engineers.

Threat:

Complex regulatory approval pathways

Evolving and inconsistent international regulations can create unforeseen compliance challenges, delaying product launches in key markets. Any post-market surveillance issues or recalls can trigger even stricter oversight, increasing operational risk and liability for manufacturers. This environment demands substantial ongoing investment in regulatory affairs, diverting resources from core R&D activities and potentially deterring investment in next-generation, higher-risk innovative products, thereby threatening long-term market advancement.

Covid-19 Impact:

The COVID-19 pandemic initially disrupted the nanotech drug implants market through severe supply chain interruptions and the halting of non-essential clinical trials, delaying product development. Elective procedure cancellations also temporarily reduced the implantation rate for certain devices. However, the crisis subsequently acted as a catalyst, highlighting the critical need for advanced, autonomous drug delivery systems that minimize hospital visits. Moreover, accelerated regulatory pathways for pandemic-related innovations and heightened investment in biomedical research are expected to benefit the market's long-term growth trajectory by fostering innovation.

The polymers segment is expected to be the largest during the forecast period

The polymers segment is expected to account for the largest market share during the forecast period due to the extensive application of biodegradable polymers like PLGA and PLA. These materials are favored for their excellent biocompatibility, tunable degradation kinetics, and proven track record in FDA-approved products. Their versatility allows for the encapsulation of a wide range of therapeutic agents, from small molecules to biologics. Additionally, their established manufacturing processes and favorable safety profile make them the material of choice for many existing and pipeline nanotech implantable drug products, solidifying their dominant position.

The smart/active implants segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the smart/active implants segment is predicted to witness the highest growth rate, driven by technological advancements in responsive drug delivery systems. These implants incorporate sensors and actuators to release therapeutics in response to specific physiological triggers, such as changes in glucose levels or enzyme activity. This capability for real-time monitoring and closed-loop feedback provides unparalleled therapeutic control for managing chronic diseases. Moreover, the integration with digital health platforms and IoT is creating a new frontier for patient data management and personalized treatment, attracting significant investment and fueling rapid growth.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, attributed to its well-established healthcare infrastructure, high healthcare expenditure, and strong presence of leading pharmaceutical and medical device companies. Furthermore, supportive government funding for nanotechnology research, a high prevalence of chronic diseases, and a relatively streamlined regulatory environment for innovative products facilitate rapid adoption. The concentration of key market players and advanced clinical research facilities in the U.S. consolidates North America's position as the revenue leader in this market.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR. This accelerated growth is fueled by expanding healthcare access, rising disposable incomes, and increasing government initiatives to modernize healthcare systems in countries like China and India. Moreover, the region presents a large and growing patient population burdened by chronic diseases, creating a substantial unmet clinical need. The growing medical tourism industry, increasing local manufacturing capabilities, and rising investments in biomedical R&D are key factors positioning Asia Pacific as the fastest-growing market for nanotech drug implants.

Key players in the market

Some of the key players in Nanotech Drug Implants Market include Abbott, AstraZeneca, Bristol-Myers Squibb, Celgene Corporation, Johnson & Johnson, Merck, Moderna, Nanobiotix, Nanoform, Novartis, Pfizer, Roche, Sanofi, Thermo Fisher Scientific, Medtronic, Straumann Holding, Gilead Sciences, and Jazz Pharmaceuticals.

Key Developments:

In September 2025, Merck disclosed FDA acceptance of the New Drug Application for DOR/ISL as a once-daily oral regimen for virologically suppressed adults with HIV-1; this is not an implant but reflects the latest islatravir program milestone.

In February 2025, Roche announced U.S. FDA approval of Susvimo (ranibizumab) 100 mg/mL for diabetic macular edema, expanding the approved use of its refillable ocular drug-delivery implant.

Product Types Covered:

  • Biodegradable implants
  • Non-biodegradable implants
  • Smart/active implants

Materials:

  • Polymers
  • Lipid-based
  • Metallic/inorganic
  • Other Materials

Therapeutic Areas Covered:

  • Oncology
  • Neurology
  • Cardiovascular
  • Endocrinology
  • Ophthalmology
  • Infectious diseases
  • Other Therapeutic Areas

Implantation Sites Covered:

  • Subcutaneous
  • Intracranial
  • Intraperitoneal
  • Intraocular
  • Other sites

End Users Covered:

  • Hospitals & clinics
  • Specialty care centers
  • Ambulatory surgical centers

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Nanotech Drug Implants Market, By Product Type

  • 5.1 Introduction
  • 5.2 Biodegradable implants
  • 5.3 Non-biodegradable implants
  • 5.4 Smart/active implants

6 Global Nanotech Drug Implants Market, By Material

  • 6.1 Introduction
  • 6.2 Polymers
  • 6.3 Lipid-based
  • 6.4 Metallic/inorganic
  • 6.5 Other Materials

7 Global Nanotech Drug Implants Market, By Therapeutic Area

  • 7.1 Introduction
  • 7.2 Oncology
  • 7.3 Neurology
  • 7.4 Cardiovascular
  • 7.5 Endocrinology
  • 7.6 Ophthalmology
  • 7.7 Infectious diseases
  • 7.8 Other Therapeutic Areas

8 Global Nanotech Drug Implants Market, By Implantation Site

  • 8.1 Introduction
  • 8.2 Subcutaneous
  • 8.3 Intracranial
  • 8.4 Intraperitoneal
  • 8.5 Intraocular
  • 8.6 Other sites

9 Global Nanotech Drug Implants Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals & clinics
  • 9.3 Specialty care centers
  • 9.4 Ambulatory surgical centers

10 Global Nanotech Drug Implants Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Abbott
  • 12.2 AstraZeneca
  • 12.3 Bristol-Myers Squibb
  • 12.4 Celgene Corporation
  • 12.5 Johnson & Johnson
  • 12.6 Merck
  • 12.7 Moderna
  • 12.8 Nanobiotix
  • 12.9 Nanoform
  • 12.10 Novartis
  • 12.11 Pfizer
  • 12.12 Roche
  • 12.13 Sanofi
  • 12.14 Thermo Fisher Scientific
  • 12.15 Medtronic
  • 12.16 Straumann Holding
  • 12.17 Gilead Sciences
  • 12.18 Jazz Pharmaceuticals

List of Tables

  • Table 1 Global Nanotech Drug Implants Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Nanotech Drug Implants Market Outlook, By Product Type (2024-2032) ($MN)
  • Table 3 Global Nanotech Drug Implants Market Outlook, By Biodegradable implants (2024-2032) ($MN)
  • Table 4 Global Nanotech Drug Implants Market Outlook, By Non-biodegradable implants (2024-2032) ($MN)
  • Table 5 Global Nanotech Drug Implants Market Outlook, By Smart/active implants (2024-2032) ($MN)
  • Table 6 Global Nanotech Drug Implants Market Outlook, By Material (2024-2032) ($MN)
  • Table 7 Global Nanotech Drug Implants Market Outlook, By Polymers (2024-2032) ($MN)
  • Table 8 Global Nanotech Drug Implants Market Outlook, By Lipid-based (2024-2032) ($MN)
  • Table 9 Global Nanotech Drug Implants Market Outlook, By Metallic/inorganic (2024-2032) ($MN)
  • Table 10 Global Nanotech Drug Implants Market Outlook, By Other Materials (2024-2032) ($MN)
  • Table 11 Global Nanotech Drug Implants Market Outlook, By Therapeutic Area (2024-2032) ($MN)
  • Table 12 Global Nanotech Drug Implants Market Outlook, By Oncology (2024-2032) ($MN)
  • Table 13 Global Nanotech Drug Implants Market Outlook, By Neurology (2024-2032) ($MN)
  • Table 14 Global Nanotech Drug Implants Market Outlook, By Cardiovascular (2024-2032) ($MN)
  • Table 15 Global Nanotech Drug Implants Market Outlook, By Endocrinology (2024-2032) ($MN)
  • Table 16 Global Nanotech Drug Implants Market Outlook, By Ophthalmology (2024-2032) ($MN)
  • Table 17 Global Nanotech Drug Implants Market Outlook, By Infectious diseases (2024-2032) ($MN)
  • Table 18 Global Nanotech Drug Implants Market Outlook, By Other Therapeutic Areas (2024-2032) ($MN)
  • Table 19 Global Nanotech Drug Implants Market Outlook, By Implantation Site (2024-2032) ($MN)
  • Table 20 Global Nanotech Drug Implants Market Outlook, By Subcutaneous (2024-2032) ($MN)
  • Table 21 Global Nanotech Drug Implants Market Outlook, By Intracranial (2024-2032) ($MN)
  • Table 22 Global Nanotech Drug Implants Market Outlook, By Intraperitoneal (2024-2032) ($MN)
  • Table 23 Global Nanotech Drug Implants Market Outlook, By Intraocular (2024-2032) ($MN)
  • Table 24 Global Nanotech Drug Implants Market Outlook, By Other sites (2024-2032) ($MN)
  • Table 25 Global Nanotech Drug Implants Market Outlook, By End User (2024-2032) ($MN)
  • Table 26 Global Nanotech Drug Implants Market Outlook, By Hospitals & clinics (2024-2032) ($MN)
  • Table 27 Global Nanotech Drug Implants Market Outlook, By Specialty care centers (2024-2032) ($MN)
  • Table 28 Global Nanotech Drug Implants Market Outlook, By Ambulatory surgical centers (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.